CSIMarket Company Name, Ticker, Customers, else..
 
Quantum Cyber N v   (MYNZ)
 
Price: $0.3228 $0.32 %
Day's High: $0.3490000069141388 Week Perf: -15.03 %
Day's Low: $ 0.30 30 Day Perf: -57.02 %
Volume (M): 324,669 52 Wk High: $ 2.09
Volume (M$): $ 0 52 Wk Avg: $1.18
Open: $0.35 52 Wk Low: $0.30



 Market Capitalization (Millions $) 6
 Shares Outstanding (Millions) 18
 Employees 202
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -36
 Cash Flow (TTM) (Millions $) -19
 Capital Exp. (TTM) (Millions $) 2

Business Description


Mainz Biomed N v is a pharmaceutical company located in Mainz, Germany. The company focuses on biomedicine and specializes in the research, development, and production of innovative drugs and medical treatments. They aim to improve patient health and quality of life through their scientific advancements. Mainz Biomed N v also collaborates with academic institutions and other pharmaceutical companies to foster innovation and bring cutting-edge therapies to market. They prioritize patient safety, efficacy, and accessibility in their product development process.


   Company Address: 1501 Belvedere Road Suite 500 West Palm Beach 33406 FL
   Company Phone Number: 562-4111   Stock Exchange / Ticker: MYNZ


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ACUT   -5%    
COIN        3.67% 
GH        1.69% 
• View Complete Report
   



Partnership

Pioneering Colorectal Cancer Screening Mainz Biomed Partners with Quest Diagnostics to Enhance Clinical Trials

Published Thu, Dec 19 2024 1:01 PM UTC

Mainz Biomed, an innovative biotechnology company focused on the development of solutions for colorectal cancer detection, has announced a significant agreement with Quest Diagnostics. This partnership aims to provide essential clinical trials laboratory services that will bolster the development of Mainz Biomed’s groundbreaking screening test.Colorectal cancer is one of t...
Stock Market Announcement

Mainz Biomed Takes a Strategic Leap: Harnessing AI for Breakthrough Diagnostics Amid New Funding

Published Fri, Dec 13 2024 1:00 AM UTC

In a significant development within the biopharmaceutical landscape, Mainz Biomed, a dedicated player in the field of molecular genetic testing, has announced the completion of an $8.0 million follow-on offering priced under the at-the-market (ATM) provisions of Nasdaq rules. This financial move comes on the heels of the company s recent unveiling of a strategic initiative a...
Management Announcement

A New Era in Diagnostics: Mainz Biomeds Strategic Leap Towards AI-Enhanced Biomarker Discovery and FDA Trials

Published Tue, Oct 1 2024 12:01 PM UTC

In the ever-evolving landscape of healthcare, the integration of artificial intelligence (AI) has become a cornerstone of innovation, particularly in the challenging field of cancer diagnostics. Mainz Biomed N.V. (NASDAQ: MYNZ) stands at the forefront of this transformation, spearheading advancements aimed at early detection and management of pancreatic diseases through its ...
Partnership

Harnessing AI for Enhanced Biomarker Selection Mainz Biomeds Strategic Partnership with Liquid Biosciences

Published Wed, Sep 4 2024 8:01 AM UTC

Artificial Intelligence (AI) has emerged as a pivotal tool in pharmaceutical sciences, particularly in the realm of biomarker discovery. In this context, Mainz Biomed N.V. (NASDAQ: MYNZ) has announced a strategic partnership with Liquid Biosciences aimed at leveraging AI to enhance the selection and optimization of biomarkers for its PancAlert platform. This development sig...
Product Service News

In a significant stride toward optimizing colon cancer screening, Mainz Biomed recently unveiled the latest...

Published Thu, Jul 25 2024 12:01 PM UTC

Enhanced ColoAlert: Mainz Biomed Revolutionizes Colon Cancer Screening with Advanced Features and Unmatched User Convenience In a significant stride toward optimizing colon cancer screening, Mainz Biomed recently unveiled the latest iteration of its flagship product, ColoAlert. Emphasizing remarkable advancements in screening efficiency and user convenience, the enhanced Col...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 10.73
Price to Sales (Expected) -
Price to Book 0.28
PEG (TTM) -

Financial Strength Current
Quick Ratio 4.46
Working Capital Ratio 5.64
Leverage Ratio (MRQ) 0.15
Total Debt to Equity 0.01
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -2.56 $
Revenues (TTM) 0.03 $
Cash Flow (TTM) -
Cash 0.75 $
Book Value 1.14 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -177,173
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.